Indivior Pharmaceuticals Inc
INDVNASDAQHealthcare● Active
$37.90
+$0.29(+0.76%)
Market Cap$4.7B
P/E Ratio—
52W High$41
52W Low$13.42
Indivior Pharmaceuticals Inc (INDV) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
INDV · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
$0.96
Est. $0.64 · +50.0%
Revenue
$0.32B
Est. $0.27B · +16.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 8-Quarter EPS Beat Streak
INDV reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | $0.83 | — | — | — | $0.30B | — |
| ▲ Q2 FY2026 | Apr 30, 2026 | $0.64 | $0.96 | +50.0% | $0.32B | $0.27B | +16.2% |
| ▲ Q1 FY2026 | Feb 26, 2026 | $0.65 | $0.82 | +26.1% | $0.36B | $0.31B | +17.1% |
| ▲ Q4 FY2025 | Oct 30, 2025 | $0.38 | $0.72 | +89.5% | $0.31B | $0.31B | +2.5% |
| ▲ Q3 FY2025 | Jul 31, 2025 | $0.26 | $0.51 | +96.2% | $0.30B | $0.26B | +18.3% |
| ▲ Q2 FY2025 | Apr 24, 2025 | $0.22 | $0.41 | +86.4% | $0.27B | $0.24B | +9.8% |
| — Q1 FY2025 | Feb 20, 2025 | $0.32 | $0.32 | +0.0% | $0.30B | $0.24B | +24.5% |
| ▲ Q4 FY2024 | Oct 24, 2024 | $0.31 | $0.54 | +74.2% | $0.31B | $0.26B | +17.9% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$0.83
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Beat
EPS Actual
$0.96
EPS Est.
$0.64
EPS Surpr.
+50.0%
Revenue
$0.32B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
$0.82
EPS Est.
$0.65
EPS Surpr.
+26.1%
Revenue
$0.36B
Q4 FY2025
Oct 30, 2025Beat
EPS Actual
$0.72
EPS Est.
$0.38
EPS Surpr.
+89.5%
Revenue
$0.31B
Q3 FY2025
Jul 31, 2025Beat
EPS Actual
$0.51
EPS Est.
$0.26
EPS Surpr.
+96.2%
Revenue
$0.30B
Q2 FY2025
Apr 24, 2025Beat
EPS Actual
$0.41
EPS Est.
$0.22
EPS Surpr.
+86.4%
Revenue
$0.27B
Q1 FY2025
Feb 20, 2025
EPS Actual
$0.32
EPS Est.
$0.32
EPS Surpr.
+0.0%
Revenue
$0.30B
Q4 FY2024
Oct 24, 2024Beat
EPS Actual
$0.54
EPS Est.
$0.31
EPS Surpr.
+74.2%
Revenue
$0.31B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.24 | $1.30 | $1.35 | 1 |
| Q3 FY2028 | $1.15 | $1.20 | $1.25 | 1 |
| Q2 FY2028 | $1.09 | $1.14 | $1.18 | 1 |
| Q1 FY2028 | $0.92 | $0.96 | $1.00 | 1 |
| Q4 FY2027 | $1.07 | $1.12 | $1.16 | 1 |
| Q3 FY2027 | $1.05 | $1.10 | $1.14 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.4B | $0.4B | $0.4B | 1 |
| Q3 FY2028 | $0.3B | $0.4B | $0.4B | 1 |
| Q2 FY2028 | $0.3B | $0.4B | $0.4B | 1 |
| Q1 FY2028 | $0.3B | $0.3B | $0.4B | 1 |
| Q4 FY2027 | $0.3B | $0.3B | $0.4B | 1 |
| Q3 FY2027 | $0.3B | $0.3B | $0.3B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 30, 2026 | +50.0% | $34.15 | $36.78 | +7.70% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +26.1% | $33.63 | $33.71 | +0.24% |
| ▲ Q4 FY2025 | Oct 30, 2025 | +89.5% | $25.24 | $29.13 | +15.41% |
| ▲ Q3 FY2025 | Jul 31, 2025 | +96.2% | $17.40 | $20.20 | +16.09% |
| ▲ Q2 FY2025 | Apr 24, 2025 | +86.4% | $9.45 | $10.76 | +13.86% |
| ▲ Q1 FY2025 | Feb 20, 2025 | +0.0% | $10.91 | $8.99 | -17.60% |
| ▲ Q4 FY2024 | Oct 24, 2024 | +74.2% | $8.56 | $8.77 | +2.45% |
| ▲ Q3 FY2024 | Jul 25, 2024 | +10.0% | $10.88 | $13.09 | +20.31% |
Q2 FY2026+7.70%
Report Date
Apr 30, 2026
EPS Beat/Miss
+50.0%
Price Before
$34.15
Price After
$36.78
Q1 FY2026+0.24%
Report Date
Feb 26, 2026
EPS Beat/Miss
+26.1%
Price Before
$33.63
Price After
$33.71
Q4 FY2025+15.41%
Report Date
Oct 30, 2025
EPS Beat/Miss
+89.5%
Price Before
$25.24
Price After
$29.13
Q3 FY2025+16.09%
Report Date
Jul 31, 2025
EPS Beat/Miss
+96.2%
Price Before
$17.40
Price After
$20.20
Q2 FY2025+13.86%
Report Date
Apr 24, 2025
EPS Beat/Miss
+86.4%
Price Before
$9.45
Price After
$10.76
Q1 FY2025-17.60%
Report Date
Feb 20, 2025
EPS Beat/Miss
+0.0%
Price Before
$10.91
Price After
$8.99
Q4 FY2024+2.45%
Report Date
Oct 24, 2024
EPS Beat/Miss
+74.2%
Price Before
$8.56
Price After
$8.77
Q3 FY2024+20.31%
Report Date
Jul 25, 2024
EPS Beat/Miss
+10.0%
Price Before
$10.88
Price After
$13.09
Avg Beat Reaction+7.31%
Beat Rate8 / 8 quarters
Largest Move+20.31% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: INDV ends December
Indivior Pharmaceuticals Inc (INDV) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $0.96 — beating the analyst consensus of $0.64 by +50.0%. INDV has beaten EPS estimates for 8 consecutive quarters. The next INDV earnings date is expected around September 1, 2026.
Each quarter, investors track INDV earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. INDV revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
INDV's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
INDV earnings · 5 questionsIndivior Pharmaceuticals Inc's next earnings report is expected around September 1, 2026. INDV typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; INDV historically reports after market close (AMC).
INDV earnings datewhen is INDV earningsINDV next earnings datewhen does INDV report earningsINDV earnings calendar
▸ Source: FMP · Indivior Pharmaceuticals Inc SEC filings · US GAAP · Indivior Pharmaceuticals Inc SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026